Antibody Response to Pneumococcal, Influenza, and COVID-19 Vaccination in Patients With Multiple Myeloma.

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-02-15 DOI:10.1016/j.clml.2025.02.006

Pranjal Singh, Charanpreet Singh, Kamaljeet Kamaljeet, Vijayalakshmi Aravindan Arun, Radha Kanta Ratho, Archana Angrup, Arihant Jain, Sreejesh Sreedharanunni, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra

{"title":"Antibody Response to Pneumococcal, Influenza, and COVID-19 Vaccination in Patients With Multiple Myeloma.","authors":"Pranjal Singh, Charanpreet Singh, Kamaljeet Kamaljeet, Vijayalakshmi Aravindan Arun, Radha Kanta Ratho, Archana Angrup, Arihant Jain, Sreejesh Sreedharanunni, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra","doi":"10.1016/j.clml.2025.02.006","DOIUrl":null,"url":null,"abstract":"Introduction: Vaccination for common pathogens implicated in causing respiratory illness in patients with Multiple Myeloma (MM) is now recommended by most experts. However, there is limited data regarding the effectiveness of vaccination in these patients.Methods: We conducted a prospective study on the efficacy of pneumococcal, influenza, and COVID-19 vaccination in patients with newly diagnosed MM treated at our center between January and June 2021.Results: Thirty patients completed the vaccination and were analyzed for the effectiveness of the vaccines. A significant rise in pneumococcal (2.87 U/ml vs. 0.68 U/ml; P < .001), Influenza (0.25 IU/L vs. 0.08 IU/L; P < 0.001) and COVID-19 (3.86 IU/L vs. 0.24 IU/L; P < .001) antibody titres was seen in our patients. Nineteen patients (63.3%), 16 patients (53.3%), and 16 patients (53.3%) achieved seroconversion for pneumococcus, influenza, and COVID-19 postvaccination, respectively, and exhibited a 4-fold rise in antibody titer. No serious adverse events were reported after vaccination in the cohort. During the 6-month follow-up, ten patients developed respiratory tract infections- 4 with lower respiratory tract and 6 with upper respiratory tract infections. None of the patients had infections attributable to pneumococcus, influenza, or COVID-19.Conclusion: Our study showed a 50% to 60% seroconversion after vaccination against 3 common respiratory pathogens in patients with newly diagnosed MM.","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.02.006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Vaccination for common pathogens implicated in causing respiratory illness in patients with Multiple Myeloma (MM) is now recommended by most experts. However, there is limited data regarding the effectiveness of vaccination in these patients.

Methods: We conducted a prospective study on the efficacy of pneumococcal, influenza, and COVID-19 vaccination in patients with newly diagnosed MM treated at our center between January and June 2021.

Results: Thirty patients completed the vaccination and were analyzed for the effectiveness of the vaccines. A significant rise in pneumococcal (2.87 U/ml vs. 0.68 U/ml; P < .001), Influenza (0.25 IU/L vs. 0.08 IU/L; P < 0.001) and COVID-19 (3.86 IU/L vs. 0.24 IU/L; P < .001) antibody titres was seen in our patients. Nineteen patients (63.3%), 16 patients (53.3%), and 16 patients (53.3%) achieved seroconversion for pneumococcus, influenza, and COVID-19 postvaccination, respectively, and exhibited a 4-fold rise in antibody titer. No serious adverse events were reported after vaccination in the cohort. During the 6-month follow-up, ten patients developed respiratory tract infections- 4 with lower respiratory tract and 6 with upper respiratory tract infections. None of the patients had infections attributable to pneumococcus, influenza, or COVID-19.

Conclusion: Our study showed a 50% to 60% seroconversion after vaccination against 3 common respiratory pathogens in patients with newly diagnosed MM.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.